Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

G0776

Sigma-Aldrich

Disialoganglioside-GD2 from bovine brain

~95%, lyophilized powder, semisynthetic

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Número de CAS:
65988-71-8
Número MDL:
MFCD00131133
Código UNSPSC:
12352200
NACRES:
NA.77
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Nivel de calidad

200

Ensayo

~95%

Formulario

lyophilized powder

temp. de almacenamiento

−20°C

InChI

1S/C74H134N4O32/c1-4-6-8-10-12-14-16-18-19-21-23-25-27-29-31-33-52(89)78-43(44(84)32-30-28-26-24-22-20-17-15-13-11-9-7-5-2)40-101-69-61(95)60(94)63(50(38-81)104-69)106-70-62(96)67(64(51(39-82)105-70)107-68-55(77-42(3)83)59(93)58(92)49(37-80)103-68)110-74(72(99)100)35-46(86)54(76)66(109-74)57(91)48(88)41-102-73(71(97)98)34-45(85)53(75)65(108-73)56(90)47(87)36-79/h30,32,43-51,53-70,79-82,84-88,90-96H,4-29,31,33-41,75-76H2,1-3H3,(H,77,83)(H,78,89)(H,97,98)(H,99,100)/b32-30+/t43?,44?,45-,46-,47?,48?,49-,50-,51-,53+,54+,55-,56?,57?,58+,59-,60-,61-,62-,63-,64+,65+,66+,67-,68+,69-,70+,73-,74+/m1/s1

Clave InChI

FFILOTSTFMXQJC-QCFYAKGBSA-N

Amino Acid Sequence

Cer-Glc-Gal(NeuAc-NeuAc)-GalNAc

Descripción general

Disialoganglioside GD2 is a cell surface-associated glycosphingolipid, which comprises sialic acid moiety[1] and is regarded as a carbohydrate antigen.[2]. It is expressed in the skin melanocytes, central and peripheral nervous system.[1]
Gangliosides are major constituents of neuronal cell membranes and endoplasmic reticulum; contain a sialated polysaccharide chain linked to ceramide through a β-glycosidic linkage; for classification of gangliosides see Svennerholm, L., et al. (eds.), Structure and Function of Gangliosides, New York, Plenum, 1980.

Aplicación

Disialoganglioside-GD2 from bovine brain has been used:
  • in the ganglioside- enzyme-linked immunosorbent assay (ELISA)[3]
  • in capture ELISA with anti-GD2 antibody (ch14.18)[4]
  • as a control to test its effect on reactivating autophagy in primary fibroblasts[5]

Acciones bioquímicas o fisiológicas

Disialoganglioside GD2 is expressed in neuroblastoma, melanoma and small cell lung cancer.[2] It is an immunotherapeutic target[2] and is also regarded as a tumor-associated antigen.[6] GD2 may favor cell migrationin tumors by promoting cell growth, as well as extracellular matrix component attachment.[7]

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000242359
0000242359
0000113336
0000106938
066M4082V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Fariba Navid et al.
Current cancer drug targets, 10(2), 200-209 (2010-03-06)
In the development of novel immune therapies for high-risk cancers, one goal is to find tumor targets that are not widely shared by normal cells. One such target is the surface disialoganglioside GD2. This antigen is expressed on the surface
Angelika B Riemer et al.
European journal of immunology, 36(5), 1267-1274 (2006-03-29)
The disialoganglioside GD2, a carbohydrate antigen, is expressed on all tumors of neuroectodermal origin, including melanoma, neuroblastoma, sarcoma and small cell lung cancer. Due to its specific expression on tumor surfaces, GD2 is an attractive target for immunotherapies. The mouse/human
Anastasia Shibina et al.
Journal of molecular medicine (Berlin, Germany), 91(4), 459-472 (2012-10-12)
Neuroblastoma (NB) is the most common extracranial solid tumor in children. Combining passive immunotherapy with an antibody to the disialoganglioside GD2 (ch14.18/SP2/0) and cytokines with 13-cis-retinoic acid for post-myeloablative maintenance therapy increased survival in high-risk NB, but the overall prognosis
Denis Cochonneau et al.
Cancer letters, 333(2), 194-204 (2013-02-02)
O-Acetyl-GD2 ganglioside is suitable antigen for tumor immunotherapy with specific therapeutic antibody. Here, we investigate the anti-tumor activity of O-acetyl-GD2-specific monoclonal antibody 8B6 on O-acetyl-GD2-positive tumor cells. The results indicated that mAb 8B6 induced growth inhibition of O-acetyl-GD2-expressing tumor cell
Nidale Tarek et al.
The Journal of clinical investigation, 122(9), 3260-3270 (2012-08-07)
Survival outcomes for patients with high-risk neuroblastoma (NB) have significantly improved with anti-disialoganglioside GD2 mAb therapy, which promotes NK cell activation through antibody-dependent cell-mediated cytotoxicity. NK cell activation requires an interaction between inhibitory killer cell immunoglobulin-like receptors (KIRs) and HLA
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico